How Does a Mutant Protein Drive Cancer Growth?
Researchers have solved a mystery about the most important driver of cancer development.
Complete the form below to unlock access to ALL audio articles.
“Our findings have transformed our understanding of these mutations, which help rethink how they can be targeted in the development of new cancer treatments.”
Co-corresponding author, Professor Andreas Strasser, said the findings could prevent hundreds of millions of dollars being wasted on developing ineffective drugs.
“There is research underway that is working towards finding the first therapeutics to target gain-of-function traits,” Prof Strasser, Head of WEHI’s Blood Cells and Blood Cancer Division, said.
“Our findings indicate there is no further merit in this therapeutic avenue and the focus needs to shift to restoring the mutant protein’s lost function and normal tumour suppressor ability.”
Reference: Wang Z, Burigotto M, Ghetti S, et al. Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cells. Cancer Discovery. 2023. doi: 10.1158/2159-8290.CD-23-0402
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.